Business as unusual: medical oncology services adapt and deliver during <scp>COVID</scp>‐19
Avraham Travers(Calvary Mater Newcastle Hospital), James Lynam, Janine Lombard(Calvary Mater Newcastle Hospital), Louise Plowman(Calvary Mater Newcastle Hospital), Betty Zhang(Queen's University), Laura Healey(Adidas (Germany)), Hiren Mandaliya(Lake Macquarie Private Hospital), Fiona Day(Calvary Mater Newcastle Hospital), Vishal Navani(Hunter Medical Research Institute), Gaik Tin Quah(Calvary Mater Newcastle Hospital), Gillian Blanchard(Calvary Mater Newcastle Hospital), Prajwol Shrestha(Calvary Mater Newcastle Hospital), Girish Mallesara(Calvary Mater Newcastle Hospital), Tony Bonaventura(St Vincent’s Private Hospital Sydney), Ina Nordman(Calvary Mater Newcastle Hospital), Bharti Tailor(Hunter New England Local Health District), André van der Westhuizen(Hunter Medical Research Institute), Kim Adler(Calvary Mater Newcastle Hospital), Craig Gedye(Centre for Cancer Biology), Julie Charlton(Calvary Mater Newcastle Hospital), Sang Kim(Macquarie University), Robin Paterson(Calvary Mater Newcastle Hospital), Michael Scalley(Calvary Mater Newcastle Hospital)
Cited by 9
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
|Translational Lung Cancer Research|2019|392
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
|Journal of Clinical Oncology|2022|166
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
|Nature Medicine|2023|135
Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial
|Cancer Epidemiology Biomarkers & Prevention|2016|115